Evofem biosciences, inc. (EVFM)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-19,146

-12,717

-13,798

-35,450

-18,068

-14,981

-18,431

-23,244

-69,056

-19,493

-74,031

-6,512

-5,269

-55,620

-2,362

-2,657

-6,026

-9,515

-17,262

-9,477

-6,902

-2,896

-4,040

-2,279

-1,602

Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash used in operating activities:
Loss on issuance of warrants

-

-

-

-

-

-

0

0

-47,920

-8,522

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

0

0

0

3,315

4,440

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-568

2,044

271

-886

Liabilities, Fair Value Adjustment

-

-

-

-

-

0

0

0

-130

-1,364

-59,211

-250

-350

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on notes payable and debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

60

39

58

57

57

46

33

40

7

2

Stock-based compensation

3,401

1,839

2,263

2,515

1,962

1,756

4,735

10,663

688

214

216

212

219

460

83

172

714

536

365

376

299

256

137

120

98

Loss on sale of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-0

0

-6

-

-

-

-

Depreciation

69

65

66

66

66

66

65

66

65

65

66

65

48

39

17

17

17

17

17

19

3

4

4

3

4

Noncash lease expenses

164

155

168

162

157

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid and other assets

1,027

544

-577

997

-12

-196

-258

-109

574

-7

-83

-150

95

1,620

-248

-317

-901

981

180

53

-164

-207

971

32

-12

Accounts payable

996

697

-3,150

-3,365

2,887

5,300

256

-5,721

3,964

3,910

2,184

153

805

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other liabilities

-205

-3,589

-1,010

-4,428

252

-2,934

3,388

-1,639

390

5,872

1,296

1,801

-1,650

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation

1,069

754

657

-1,465

800

363

823

600

-1,479

340

493

411

-469

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

197

185

198

192

186

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent, net of current portion

-

-

-

-

-

13

22

21

186

10

9

3

8

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash used in operating activities

-14,876

-13,446

-14,425

-19,548

-7,678

-10,247

-8,928

-19,187

-18,138

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,110

-547

-3,253

-3,691

5,272

1,273

1,578

-186

1,057

-3

-412

Net cash, cash equivalents and restricted cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-3,473

-6,069

-11,051

-3,122

-2,636

-7,606

-13,575

-11,728

-7,803

-4,803

-3,148

-1,728

-1,912

-2,782

Cash flows from investing activities:
Maturities of short-term investments

250

0

0

0

250

0

0

0

250

0

0

0

250

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

6,747

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in connection with the Merger

-

-

-

-

-

0

0

0

1,900

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

200

-

-

-

-

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

226

11

4

0

2

Purchases of property and equipment

95

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by investing activities

6,902

-4,627

-3,738

0

250

-7

0

0

2,150

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

0

250

-

-

-

-

200

0

0

-426

-11

-4

0

-2

Cash flows from financing activities:
Proceeds from issuance of common stock- exercise of warrants

0

0

0

0

6,273

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

20,000

9,925

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of commissions- ATM transactions

1,424

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepayment resulting in debt extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,000

0

5,514

-

-

-

-

-

-

-

-

Principal payments on bank loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

485

-

-

-

-

-

-

-

-

Loan amendment costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

52

-

-

-

-

-

-

-

-

Principal payments on bank loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

91

117

Proceeds from issuance of common stock - exercise of stock options

160

-

0

46

0

-

0

0

42

0

0

0

0

-

-

-

-

-

-

-

-

26

0

0

49

Payment of cash dividends for Series D redeemable convertible preferred stock

-

-

-

-

-

0

0

0

157

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of preferred stock for cash, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

5,575

0

7,992

Cash paid for financing costs

195

-

290

890

0

-

-

-

-

15

50

68

580

-

-

-

-

-

-

-

-

-

-

-

-

Payments of tax withholdings related to vesting of restricted stock awards

25

921

121

518

6

66

1,526

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by financing activities

1,364

2,192

-411

70,028

6,267

-507

-1,892

36,931

19,885

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash

-6,610

-

-

-

-1,161

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-68

-580

28,079

-3,984

18

-6,052

-

-

-

-

64,457

4,884

3,908

7,924

Net change in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-10,820

17,744

3,897

-2,464

2,618

-3,541

-6,399

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities

266

0

0

0

802

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing costs included in accounts payable and accrued expenses

13

-

-207

93

164

-

-264

408

392

-15

126

10

16

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued expenses

201

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,618

-13,658

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,684

-7,763

-5,229

-

3,151

1,995

5,138

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-591

297

135

230

382

152

152

225

127

62

159

2

Net assets acquired in connection with the Merger

-

-

-

-

-

0

0

0

46

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Convertible Preferred Stock
Conversion of Series D redeemable convertible preferred stock into common stock

-

-

-

-

-

0

0

0

121,315

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series D Convertible Preferred Stock
Conversion of Series D redeemable convertible preferred stock into common stock

-

-

-

-

-

0

0

0

68,622

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series D 2X Liquidation Preference Liability
Conversion of Series D redeemable convertible preferred stock into common stock

-

-

-

-

-

0

0

0

80,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-